Quote | Satsuma Pharmaceuticals Inc. (NYSE:STSA)
Last: | $ |
---|---|
Change Percent: | 4.02% |
Open: | $26.92 |
Close: | $28.18 |
High: | $29.07 |
Low: | $26.0107 |
Volume: | 24,266 |
Last Trade Date Time: | 02/12/2020 04:43:31 pm |
News | Satsuma Pharmaceuticals Inc. (NYSE:STSA)
DURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. , a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic produc...
January 2024 PDUFA date expected If approved, STS101 would become the only DHE product evaluated in a randomized, placebo-controlled trial (the SUMMIT trial) against modern outcome measures recommended by both the U.S. Food and Drug Administration (FDA) and International Headache Society ...
Message Board Posts | Satsuma Pharmaceuticals Inc. (NYSE:STSA)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $STSA News Article - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NATI, RXD | whytestocks | investorshangout | 04/25/2023 4:00:46 PM |
znewcar1: $STSA 64% v43,7M c1.08 f33,152M H1.47 ML.66 | znewcar1 | investorshangout | 04/18/2023 1:32:59 AM |
whytestocks: $STSA News Article - SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates RXDX, STSA, CHRA | whytestocks | investorshangout | 04/17/2023 6:20:48 PM |
whytestocks: $STSA News Article - STSA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sa | whytestocks | investorshangout | 04/17/2023 1:55:47 PM |
Loading this dip for the rip. | Jess070283 | investorshub | 04/17/2023 1:51:40 PM |
News, Short Squeeze, Breakout and More Instantly...
Satsuma Pharmaceuticals Inc. Company Name:
STSA Stock Symbol:
NYSE Market:
DURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. , a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic produc...
January 2024 PDUFA date expected If approved, STS101 would become the only DHE product evaluated in a randomized, placebo-controlled trial (the SUMMIT trial) against modern outcome measures recommended by both the U.S. Food and Drug Administration (FDA) and International Headache Society ...
NEW YORK, NY / ACCESSWIRE / May 1, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Hoth Therapeutics, Inc. (NASDAQ:HOTH)'s...